Growth Outcomes of Preterm Infants Exposed to Different Oxygen Saturation Target Ranges from Birth

Abstract

Objective To test whether infants randomized to a lower oxygen saturation (SpO2) target range while on supplemental oxygen from birth will have better growth velocity from birth to 36 weeks postmenstrual age (PMA), and less growth failure at 36 weeks PMA and 18–22 months corrected age. Study design We evaluated a subgroup of 810 preterm infants from the Surfactant, Positive Pressure, and Oxygenation Randomized Trial, randomized at birth to lower (85–89%, n=402, GA 26 ± 1wk, BW 839 ± 186 g) or higher (91–95%, n=408, GA 26 ± 1wk, BW 840 ± 191 g) SpO2 target ranges. Anthropometric measures were obtained at birth, postnatal days 7, 14, 21, and 28; then at 32 and 36 weeks PMA, and 18–22 months corrected age. Growth velocities were estimated using the exponential method and analyzed using linear mixed models. Poor growth outcome, defined as weight < 10th percentile at 36 weeks PMA and 18–22 months corrected age, was compared across the two treatment groups using robust Poisson regression. Results Growth outcomes including growth at 36 weeks PMA and 18–22 months corrected age, as well as growth velocity were similar in the lower and higher SpO2 target groups. Conclusion Targeting different oxygen saturation ranges between 85% and 95% from birth did not impact growth velocity or reduce growth failure in preterm infants.

Growth and morbidity of extremely preterm infants after early full enteral nutrition

“…It is most likely due to differences in energy and protein supply during the first postnatal weeks, and it stands to reason that early exclusive enteral feeding results in considerably higher macronutrient supply in this time period. This hypothesis is supported by a recent report on nutritional intakes in extremely premature infants5 where a mean total energy intake of 100 kcal/kg/day was not achieved until postnatal day 28.…”

Medical and developmental outcomes of bevacizumab versus laser for retinopathy of prematurity

“…32,33 Thus it is not surprising that growth and neurodevelopmental outcomes were not as good as outcomes reported for less selected groups of premature infants. 34,35 For those concerned about the systemic effects of bevacizumab on premature infants, this study should provide some reassurance that the adverse effects of bevacizumab reported in the previous large observational study were not apparent in our randomized infants.…”

Serial assessment of fat and fat-free mass accretion in very preterm infants: a randomized trial

“…However, having this type of control has not led to significant reductions in postnatal growth failure at 36 weeks of postmenstrual age (PMA). Postnatal growth failure (weight < 10 th percentile) occurs in up to 60% ( 1 – 3 ) of the nearly 80,000 infants born preterm at 32 weeks of gestation or less every year in the United States ( 4 ).…”